Srivastava T, Dhar R, Karmakar S
Reprod Biol Endocrinol. 2025; 23(1):9.
PMID: 39833837
PMC: 11744844.
DOI: 10.1186/s12958-024-01338-z.
Khatiwada P, Rimal U, Han Z, Shemshedini L
Endocr Oncol. 2024; 4(1):e230017.
PMID: 38410785
PMC: 10895308.
DOI: 10.1530/EO-23-0017.
Alemany M
Int J Mol Sci. 2022; 23(19).
PMID: 36233256
PMC: 9569951.
DOI: 10.3390/ijms231911952.
Zhou T, Feng Q
Front Med (Lausanne). 2022; 9:924087.
PMID: 35966880
PMC: 9372301.
DOI: 10.3389/fmed.2022.924087.
Wu S, Yu K, Lian Z, Deng S
Int J Mol Sci. 2022; 23(14).
PMID: 35886904
PMC: 9322163.
DOI: 10.3390/ijms23147556.
Expression of Sex Hormones in Oral Squamous Cell Carcinoma: A Systematic Review on Immunohistochemical Studies.
R S, R C, Mohideen K, Adtani P, Subramani V, Balasubramaniam M
Cureus. 2022; 14(5):e25384.
PMID: 35765387
PMC: 9233754.
DOI: 10.7759/cureus.25384.
Somatic Alterations Impact AR Transcriptional Activity and Efficacy of AR-Targeting Therapies in Prostate Cancer.
Chauhan G, Heemers H
Cancers (Basel). 2021; 13(16).
PMID: 34439101
PMC: 8393938.
DOI: 10.3390/cancers13163947.
An androgen-independent mechanism underlying the androgenic effects of 3-methylcholanthrene, a potent aryl hydrocarbon receptor agonist.
Sanada N, Gotoh-Kinoshita Y, Yamashita N, Kizu R
Toxicol Res (Camb). 2020; 9(3):271-282.
PMID: 32670558
PMC: 7329177.
DOI: 10.1093/toxres/tfaa027.
Structural Insights of Transcriptionally Active, Full-Length Androgen Receptor Coactivator Complexes.
Yu X, Yi P, Hamilton R, Shen H, Chen M, Foulds C
Mol Cell. 2020; 79(5):812-823.e4.
PMID: 32668201
PMC: 7483370.
DOI: 10.1016/j.molcel.2020.06.031.
A smart deoxyribozyme-based fluorescent sensor for in vitro detection of androgen receptor mRNA.
Bryushkova E, Gandalipov E, Nuzhina J
Beilstein J Org Chem. 2020; 16:1135-1141.
PMID: 32550928
PMC: 7277777.
DOI: 10.3762/bjoc.16.100.
Androgen Receptor Dependence.
Chaturvedi A, Dehm S
Adv Exp Med Biol. 2020; 1210:333-350.
PMID: 31900916
PMC: 8990348.
DOI: 10.1007/978-3-030-32656-2_15.
Non-nuclear AR Signaling in Prostate Cancer.
Zamagni A, Cortesi M, Zanoni M, Tesei A
Front Chem. 2019; 7:651.
PMID: 31616657
PMC: 6775214.
DOI: 10.3389/fchem.2019.00651.
Two Korean girls with complete androgen insensitivity syndrome diagnosed in infancy.
Heo Y, Ko J, Lee Y, Shin C, Yang S, Kim M
Ann Pediatr Endocrinol Metab. 2019; 23(4):220-225.
PMID: 30599484
PMC: 6312918.
DOI: 10.6065/apem.2018.23.4.220.
Current status of androgen receptor-splice variant 7 inhibitor niclosamide in castrate-resistant prostate-cancer.
Sobhani N, Generali D, DAngelo A, Aieta M, Roviello G
Invest New Drugs. 2018; 36(6):1133-1137.
PMID: 30083960
DOI: 10.1007/s10637-018-0653-2.
Ca/Calmodulin-Dependent Protein Kinase II and Androgen Signaling Pathways Modulate MEF2 Activity in Testosterone-Induced Cardiac Myocyte Hypertrophy.
Duran J, Lagos D, Pavez M, Troncoso M, Ramos S, Barrientos G
Front Pharmacol. 2017; 8:604.
PMID: 28955223
PMC: 5601904.
DOI: 10.3389/fphar.2017.00604.
Targeting AR Variant-Coactivator Interactions to Exploit Prostate Cancer Vulnerabilities.
Magani F, Peacock S, Rice M, Martinez M, Greene A, Magani P
Mol Cancer Res. 2017; 15(11):1469-1480.
PMID: 28811363
PMC: 5770277.
DOI: 10.1158/1541-7786.MCR-17-0280.
Mild androgen insensitivity syndrome (MAIS): the identification of c.1783C>T mutation in two unrelated infertile men.
Alchamat G, Madania A, Alhalabi M
BMJ Case Rep. 2017; 2017.
PMID: 28659371
PMC: 5535055.
DOI: 10.1136/bcr-2017-220361.
Molecular signaling involving intrinsically disordered proteins in prostate cancer.
Russo A, La Manna S, Novellino E, Malfitano A, Marasco D
Asian J Androl. 2016; 18(5):673-81.
PMID: 27212129
PMC: 5000787.
DOI: 10.4103/1008-682X.181817.
What's new in estrogen receptor action in the female reproductive tract.
Hewitt S, Winuthayanon W, Korach K
J Mol Endocrinol. 2016; 56(2):R55-71.
PMID: 26826253
PMC: 4733493.
DOI: 10.1530/JME-15-0254.
Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
Sun N, Huang S, Lu H, Chang T, Chao C
Oncotarget. 2015; 6(29):27065-82.
PMID: 26318424
PMC: 4694974.
DOI: 10.18632/oncotarget.4824.